Molecular mechanism elucidation of gastric and intestinal differentiation and development of differentiation-inducing therapy against stem cell
| Project/Area Number |
26460945
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
谷田 諭史 名古屋市立大学, 大学院医学研究科, 講師 (30528782)
城 卓志 名古屋市立大学, 大学院医学研究科, 教授 (30231369)
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | in vitro三次元培養腺管 / 胃幹細胞 / in vitro 三次元培養腺管 |
|---|
| Outline of Final Research Achievements |
The analyses in long-term three-dimensional method for primary mouse glandular stomach culture have shown that the gastric mesenchymal myofibroblast (GMF) is important for the differentiation and proliferation of gastric epithelial cell. Growth arrest specific 1（GAS1）expression is higher in GMF, and Homeobox C8（HoxC8）、Notch 1、SRY-box containing gene 10（Sox10） are higher in intestinal mesenchymal myofibroblast, suggesting that these factors play the key roles in the gastric and intestinal differentiation by epithelial-mesenchymal interactions. We consider that the ectopic MUC5AC expression in the intestinal epithelial cells may be a predictive factor of recurrence or remission in the cases of Crohn's disease and intestinal Behçet's disease.
|
Report
(5 results)
Research Products
(18 results)
-
[Journal Article] Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy2017
Author(s)
Mizoshita, T., Katano, T., Tanida, S., Hirano, A., Miyaki, T., Ozeki, K., Suzuki, Y., Sugimura, N., Kataoka, H. & Joh, T.
-
Journal Title
Medicine (Baltimore)
Volume: 96
Issue: 32
Pages: e7800-e7800
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Adalimumab therapy in a patient with Crohn's disease with a giant pelvic paraganglioma after chemotherapy.2017
Author(s)
Mizoshita T, Ando M, Sagawa H, Mori Y, Katano T, Ozeki K, Tanida S, Okamoto Y, Shimura T, Kubota E, Kataoka H, Kamiya T, Joh T.
-
Journal Title
Clin J Gastroenterol.
Volume: in press
Issue: 3
Pages: 250-254
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
[Journal Article] Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab.2016
Author(s)
Mizoshita T, Tanida S, Ozeki K, Katano T, Shimura T, Mori Y, Kubota E, Kataoka H, Kamiya T, Joh T.
-
Journal Title
Case Rep Gastroenterol.
Volume: 10
Issue: 2
Pages: 283-91
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
[Journal Article] Preventive effect of rebamipide on N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats.2015
Author(s)
Tsukamoto H, Mizoshita T, Katano T, Hayashi N, Ozeki K, Ebi M, Shimura T, Mori Y, Tanida S, Kataoka H, Tsukamoto T, Tatematsu M, Joh T.
-
Journal Title
Toxicol Pathol.
Volume: 67
Issue: 3
Pages: 271-277
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-
-
